滚动资讯
FierceBiotechWhoop raises $575M series G, Abbott comes on board amid hiring spreeEndpoints NewsOric to advance prostate cancer drug to Phase 3, but combo choice raises doubtsLonza NewsLonza: Growth Intact, CHI Exit Strengthens Focus, Recent Dip Opens Opportunity (LZAGY) - Seeking AlphaThermo FisherRockland Trust Co. Has $34.27 Million Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeatLonza NewsLonza Group (OTCMKTS:LZAGY) Stock Passes Below 50 Day Moving Average - What's Next? - MarketBeatFierceBiotechKBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo NordiskThermo FisherThermo Fisher’s Glacios 3 Cryo TEM Puts AI At Center Of Growth - simplywall.stLonza NewsLonza Raises Dividend, Refreshes Board and Publishes 2025 Reports Ahead of 2026 AGM - TipRanksIlluminaShould Labcorp’s Expanded Illumina Oncology Partnership Reshape the Precision Medicine Story for LH Investors? - simplywall.steLifeTwo binding sites are better than one10x Genomics Blog10x Genomics (TXG) Receives Upgrade to 'Outperform' by William B - GuruFocusThermo Fisher[Form 4] THERMO FISHER SCIENTIFIC INC. Insider Trading Activity - Stock Titan
Endpoints News 2026年4月1日

Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts

Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts

原文
暂时没有全文，请查看原始来源。

目录

59 全部